Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel, Open-Label Study to Compare Once Per Day Sevelamer Carbonate Powder Dosing With Three Times Per Day Sevelamer Hydrochloride Tablet Dosing in Chronic Kidney Disease Patients on Hemodialysis

NCT00268957 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00268957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00268957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel, Open-Label Study to Compare Once Per Day Sevelamer Carbonate Powder Dosing With Three Times Per Day Sevelamer Hydrochloride Tablet Dosing in Chronic Kidney Disease Patients on Hemodialysis
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
May 31, 2007
Enrollment
217 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal insufficiency, end-stage renal disease, kidney diseases